Pteridines useful as HCV inhibitors and methods for the preparation thereof
The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
1. A compound of the formula (VII):
or a salt, stereoisomeric form, or racemic mixture thereof, wherein
R 1 is hydrogen;
R 8 is hydrogen and R 9 is —CONR 4a R 4b ;
or
R 8 is phenylC 1-4 alkyl and R 9 is hydrogen;
R 4a is hydrogen;
and R 4b is 2-oxo-pyrrolidin-1-yl-C 1-4 alkyl.
2. The compound according to claim 1 of the formula (VIII):
3. The compound according to claim 2 , wherein R 8 is phenylC 1-4 alkyl and R 9 is hydrogen.
4. The compound according to claim 1 that is
5. The compound according to claim 1 that is
6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.
7. The pharmaceutical composition according to claim 6 , further comprising one or more other anti-hepatitis C virus agents.